Dr. Pande is a scientist with a wide breadth of experience in the field of toxicology and molecular genetics. He has obtained Ph.D. from the University of Connecticut USA and master’s degree from the University of Houston Clear-Lake. He is currently working as Associate Scientific director at Janssen Pharmaceuticals USA in the genetic toxicology department. At Janssen, he is actively involved in developing strategy to assess the off-target effects and insertional mutagenesis of the lentivirus and CRISPR therapeutics. Previously, he had worked at the Boehringer Ingelheim Pharmaceuticals for 10 years in the investigative toxicology department, where he supported biomarkers and toxicogenomic assessments of the preclinical phase I enabling studies. He has also supported the safety strategy of AAV based therapeutics. Dr. Pande has over 15 years of experience in the field of toxicology and developed expertise in the field of molecular genetics. He is actively involved in the external consortiums like HESI CT-TRACs where he’s currently leading a workstream to answer questions related to genomic stability in the allogeneic iPSC derived CAR-T therapeutics.
